IC
ESPR

Ikarian Capital’s Esperion Therapeutics ESPR Stock Holding History

Ikarian Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,296,900
Closed -$8.08M – 125
2022
Q4 		$8.08M Buy
1,296,900
+1,096,900
+548% +$7.84M 1.95% 15
2022
Q3 		$1.34M Buy
+200,000
New +$1.37M 0.27% 63

Other funds holding ESPR

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Ikarian Capital's ESPR Position: Q1 2024 in Review

Ikarian Capital sold out of Esperion Therapeutics (ESPR) in Q1 2024, closing a stake of 337,636 shares — an estimated $1.01M sold.

Ikarian Capital first reported a position in ESPR in Q2 2022 and held it in 7 quarters. The position peaked at $14.3M in Q3 2022. 153 funds tracked by Wall St. Rank hold ESPR as of Q1 2024.

  • Ikarian Capital reported no remaining Esperion Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ikarian Capital sold 337,636 Esperion Therapeutics shares in Q1 2024, an estimated $1.01M.
  • Ikarian Capital first reported a position in Esperion Therapeutics in Q2 2022 and held it in 7 quarters.
  • Ikarian Capital's Esperion Therapeutics position peaked at $14.3M in Q3 2022.
  • 153 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2024.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.